CHICAGO--(BUSINESS WIRE)--Zacks Equity Research highlights AMAG Pharmaceuticals Inc. (Nasdaq: AMAG) as the Bull of the Day and Palm, Inc. (Nasdaq: PALM) the Bear of the Day. In addition, Zacks Equity Research provides analysis on Everest Re (NYSE: RE), Ace Limited (NYSE: ACE) and Montpelier (NYSE: MRH).

Full analysis of all these stocks is available at http://at.zacks.com/?id=2676.

Here is a synopsis of all five stocks:

Bull of the Day:

AMAG Pharmaceuticals Inc. (Nasdaq: AMAG) develops superparamagnetic iron oxide nanoparticles for use in pharmaceutical products. The company's focus is on developing IV iron replacement therapy for anemia in chronic kidney disease and imaging agent to aid in diagnosis.

The company filed the NDA for its lead drug Feraheme in December 2007, and the drug was approved by the FDA on June 30, 2009. Clinical data in over 1,700 patients indicate an excellent safety profile for the drug with lower incidents of heart problems.

Clinical results and eventual approval for additional indications should ensure strong growth in the coming years. We maintain our Buy rating on the shares of AMAG with a target price of $62.

Bear of the Day:

Although 4Q09 revenue declined by 70.7% y-o-y and the loss increased y-o-y, results for Palm, Inc.'s (Nasdaq: PALM) quarter were better than expected due to the ramp up in Treo Pro shipments and strong domestic and international carrier interest in its Web OS platform.

Although Palm has had some initial success with the Pre, its next-gen phone, we have doubts on its success as it competes with several much larger competitors such as BlackBerry and iPhone. As the Palm Pre was launched in June, we expect that its impact will be better reflected in the first quarter of fiscal 2010.

Palm has struggled to match supply with demand for the new handset. We have a low confidence on long-term prospects, so we reiterate our Sell rating on Palm but raise our six-month price target to $8.00.

Latest Posts on the Zacks Analyst Blog:

Reinsurance Rates Stable

In the first half of 2009, the reinsurance industry has not experienced any major underwriting losses. Also, there are some early signs of recovery in the financial sector. In addition, reinsurance companies took some desperate steps in the early part of 2009 to curb any significant deterioration in their balance sheets.

We also remain concerned about the primary insurance market, where there is still an absence of meaningful rate increases. Further, in the U.S. Casualty market, some new insurance companies are entering and thereby bringing in more capital in the industry and resulting in significant rate competition.

Though companies such as Everest Re (NYSE: RE), Ace Limited (NYSE: ACE) and Montpelier (NYSE: MRH) have experienced rates increases this year; we believe that this "sufficient availability of capital" in the market will restrict any hefty rate increases in the industry and hence confine the top-line growth of the companies.

Get the full analysis of all these stocks by going to http://at.zacks.com/?id=2649.

About the Bull and Bear of the Day

Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.

About the Analyst Blog

Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=2677.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Zacks.com
Mark Vickery
312-265-9380
Visit: www.zacks.com